Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline
Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer.
METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population.
RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria.
RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
1015-1027
Shroff, Rachna T.
beec946b-4bd0-4e71-8dc8-39b34003a6a3
Kennedy, Erin B.
269c871d-d765-4791-bb10-8b4af534e709
Bachini, Melinda
3c54f897-0d67-4e35-9fa5-61b2570b3655
Bekaii-Saab, Tanios
80106aab-ee15-421a-9a5f-b30156af3609
Crane, Christopher
cac1a02f-e7c7-4be6-9157-0bddf08320da
Edeline, Julien
76d830e6-0012-48b8-b47c-9177618074a4
El-Khoueiry, Anthony
2218e999-4d39-45d1-a757-a8862e688634
Feng, Mary
5ca423a7-2c42-4413-a322-1c63ebead4ac
Katz, Matthew H.G.
f993d8d2-7768-4c32-b904-9d94360c022b
Primrose, John
d85f3b28-24c6-475f-955b-ec457a3f9185
Soares, Heloisa P.
334146ee-9fd4-441b-968d-de3ed84b4c78
Valle, Juan
33830bc4-19fa-4140-af0d-1b1add1fbc6b
Maithel, Shishir K.
2fc5087a-8c26-49c2-bb44-34cd70b258b9
20 April 2019
Shroff, Rachna T.
beec946b-4bd0-4e71-8dc8-39b34003a6a3
Kennedy, Erin B.
269c871d-d765-4791-bb10-8b4af534e709
Bachini, Melinda
3c54f897-0d67-4e35-9fa5-61b2570b3655
Bekaii-Saab, Tanios
80106aab-ee15-421a-9a5f-b30156af3609
Crane, Christopher
cac1a02f-e7c7-4be6-9157-0bddf08320da
Edeline, Julien
76d830e6-0012-48b8-b47c-9177618074a4
El-Khoueiry, Anthony
2218e999-4d39-45d1-a757-a8862e688634
Feng, Mary
5ca423a7-2c42-4413-a322-1c63ebead4ac
Katz, Matthew H.G.
f993d8d2-7768-4c32-b904-9d94360c022b
Primrose, John
d85f3b28-24c6-475f-955b-ec457a3f9185
Soares, Heloisa P.
334146ee-9fd4-441b-968d-de3ed84b4c78
Valle, Juan
33830bc4-19fa-4140-af0d-1b1add1fbc6b
Maithel, Shishir K.
2fc5087a-8c26-49c2-bb44-34cd70b258b9
Shroff, Rachna T., Kennedy, Erin B., Bachini, Melinda, Bekaii-Saab, Tanios, Crane, Christopher, Edeline, Julien, El-Khoueiry, Anthony, Feng, Mary, Katz, Matthew H.G., Primrose, John, Soares, Heloisa P., Valle, Juan and Maithel, Shishir K.
(2019)
Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline.
Journal of Clinical Oncology, 37 (12), .
(doi:10.1200/JCO.18.02178).
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer.
METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population.
RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria.
RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Text
JCO.18.02178
- Version of Record
Available under License Other.
More information
Accepted/In Press date: 12 December 2018
e-pub ahead of print date: 11 March 2019
Published date: 20 April 2019
Identifiers
Local EPrints ID: 429254
URI: http://eprints.soton.ac.uk/id/eprint/429254
ISSN: 1527-7755
PURE UUID: 52c34e7f-af25-41f4-872c-a56df848d5f4
Catalogue record
Date deposited: 25 Mar 2019 17:30
Last modified: 16 Mar 2024 07:41
Export record
Altmetrics
Contributors
Author:
Rachna T. Shroff
Author:
Erin B. Kennedy
Author:
Melinda Bachini
Author:
Tanios Bekaii-Saab
Author:
Christopher Crane
Author:
Julien Edeline
Author:
Anthony El-Khoueiry
Author:
Mary Feng
Author:
Matthew H.G. Katz
Author:
Heloisa P. Soares
Author:
Juan Valle
Author:
Shishir K. Maithel
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
